|Mr. Robert Etherington MBA||CEO, President & Director||590.98k||N/A||1967|
|Mr. Morgan R. Brown CPA, M.B.A.||Chief Financial Officer||374.05k||N/A||1968|
|Mr. Mark G. Mortenson ESQ.||Chief Science Officer||482.98k||N/A||1958|
|Mr. Jerry Miraglia J.D.||General Counsel & Corporate Secretary||N/A||N/A||N/A|
|Mr. Michael T. Hotchkin||Chief Development Officer||N/A||N/A||N/A|
|Ms. Mary Anne Mcneil||Head of Human Resources||N/A||N/A||N/A|
|Dr. Benjamin M. Greenberg M.D., M.H.S.||Head of Medical||N/A||N/A||N/A|
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Clene Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.